These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 20719481)

  • 1. [Drugs news].
    Autret-Leca E
    Arch Pediatr; 2010 Nov; 17(11):1596-603. PubMed ID: 20719481
    [No Abstract]   [Full Text] [Related]  

  • 2. [Drug news].
    Autret-Leca E
    Arch Pediatr; 2008 Aug; 15(8):1349-55. PubMed ID: 18585013
    [No Abstract]   [Full Text] [Related]  

  • 3. [Drug news].
    Autret-Leca E
    Arch Pediatr; 2009 Feb; 16(2):146-52. PubMed ID: 19091531
    [No Abstract]   [Full Text] [Related]  

  • 4. [Drugs news].
    Autret-Leca E
    Arch Pediatr; 2009 Dec; 16(12):1587-94. PubMed ID: 19853424
    [No Abstract]   [Full Text] [Related]  

  • 5. [Drugs news].
    Autret-Leca E
    Arch Pediatr; 2005 Dec; 12(12):1748-51. PubMed ID: 16219451
    [No Abstract]   [Full Text] [Related]  

  • 6. Postmarketing surveillance for drug safety: surely we can do better.
    Griffin MR; Stein CM; Ray WA
    Clin Pharmacol Ther; 2004 Jun; 75(6):491-4. PubMed ID: 15179403
    [No Abstract]   [Full Text] [Related]  

  • 7. Which drugs to prescribe.
    Ebell M
    Fam Pract Manag; 2006 Sep; 13(8):23-4; author reply 24. PubMed ID: 17024760
    [No Abstract]   [Full Text] [Related]  

  • 8. [Drugs news].
    Autret-Leca E
    Arch Pediatr; 2006 Nov; 13(11):1454-9. PubMed ID: 17008070
    [No Abstract]   [Full Text] [Related]  

  • 9. New drugs: how to decide which ones to prescribe.
    Mohler PJ
    Fam Pract Manag; 2006 Jun; 13(6):33-5. PubMed ID: 16813119
    [No Abstract]   [Full Text] [Related]  

  • 10. [Postmarketing herbs clinical evaluation should concern about re-evaluating symptoms].
    He W; Xie Y; Wang Y
    Zhongguo Zhong Yao Za Zhi; 2010 Jun; 35(11):1498-500. PubMed ID: 20822030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of essential drugs. Sixth report of the WHO Expert Committee.
    World Health Organ Tech Rep Ser; 1995; 850():1-137. PubMed ID: 7597816
    [No Abstract]   [Full Text] [Related]  

  • 12. Safe and effective drug therapy in older adults.
    Hume AL
    Med Health R I; 2005 Jan; 88(1):15-7. PubMed ID: 15779550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Drugs news].
    Autret-Leca E
    Arch Pediatr; 2004 May; 11(5):456-9. PubMed ID: 15135431
    [No Abstract]   [Full Text] [Related]  

  • 14. New drugs: watch out for unexpected adverse effects.
    Prescrire Int; 2002 Oct; 11(61):150-1. PubMed ID: 12378747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacologic surveillance and safety evaluation of new drugs].
    Reys LL
    Acta Med Port; 1991; 4(3):141-6. PubMed ID: 1950664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Post-marketing surveillance of drugs: epidemiologic approach].
    Stanulović M; Jakovljević V; Sabo A
    Med Pregl; 1987; 40(11-12):573-7. PubMed ID: 3331415
    [No Abstract]   [Full Text] [Related]  

  • 17. Postmarketing surveillance.
    Oleen MA
    Can J Hosp Pharm; 1987 Oct; 40(5):171-2, 179-80. PubMed ID: 10284449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [How to report side-effects of drugs?].
    Guillaume JC
    Ann Dermatol Venereol; 1986; 113(4):375-6. PubMed ID: 3767239
    [No Abstract]   [Full Text] [Related]  

  • 19. Evaluating drugs after their approval for clinical use.
    Ray WA; Griffin MR; Avorn J
    N Engl J Med; 1993 Dec; 329(27):2029-32. PubMed ID: 8018139
    [No Abstract]   [Full Text] [Related]  

  • 20. The need for human data: the role of clinical trials and postmarketing surveillance in the safety assessment of macronutrient substitutes.
    Forbes AL
    Regul Toxicol Pharmacol; 1996 Feb; 23(1 Pt 2):S20-1; discussion S31-7. PubMed ID: 8801611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.